$41.84 Million in Sales Expected for Health Catalyst (NASDAQ:HCAT) This Quarter

Equities analysts expect that Health Catalyst (NASDAQ:HCAT) will post sales of $41.84 million for the current quarter, Zacks reports. Five analysts have provided estimates for Health Catalyst’s earnings, with estimates ranging from $40.95 million to $42.66 million. Health Catalyst posted sales of $36.80 million during the same quarter last year, which would indicate a positive year-over-year growth rate of 13.7%. The business is expected to issue its next earnings results on Thursday, August 27th.

On average, analysts expect that Health Catalyst will report full year sales of $181.83 million for the current financial year, with estimates ranging from $174.30 million to $186.99 million. For the next financial year, analysts forecast that the company will report sales of $218.73 million, with estimates ranging from $200.80 million to $227.77 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side analysts that follow Health Catalyst.

Health Catalyst (NASDAQ:HCAT) last announced its quarterly earnings data on Tuesday, May 12th. The company reported ($0.16) EPS for the quarter, beating the consensus estimate of ($0.25) by $0.09. The firm had revenue of $45.12 million for the quarter, compared to analyst estimates of $44.12 million. Health Catalyst had a positive return on equity of 30.42% and a negative net margin of 38.74%. Health Catalyst’s revenue for the quarter was up 28.1% compared to the same quarter last year.

Several equities research analysts recently weighed in on HCAT shares. SunTrust Banks increased their target price on Health Catalyst from $30.00 to $36.00 and gave the company a “buy” rating in a report on Wednesday, May 13th. SVB Leerink increased their target price on Health Catalyst from $31.00 to $32.00 and gave the company an “outperform” rating in a report on Wednesday, May 13th. Raymond James dropped their target price on Health Catalyst from $46.00 to $40.00 and set a “strong-buy” rating for the company in a report on Wednesday, May 13th. Guggenheim started coverage on Health Catalyst in a report on Friday, May 15th. They set a “buy” rating and a $33.00 target price for the company. Finally, Royal Bank of Canada increased their target price on Health Catalyst from $30.00 to $34.00 and gave the company an “outperform” rating in a report on Wednesday, May 13th. One research analyst has rated the stock with a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $40.33.

HCAT stock remained flat at $$28.36 during trading on Monday. The company had a trading volume of 422,400 shares, compared to its average volume of 665,889. The firm has a market capitalization of $1.08 billion and a price-to-earnings ratio of -5.37. Health Catalyst has a 52 week low of $17.48 and a 52 week high of $49.85. The stock has a 50-day moving average of $26.65 and a 200-day moving average of $31.08. The company has a debt-to-equity ratio of 0.24, a current ratio of 4.95 and a quick ratio of 4.95.

In other news, COO Paul Horstmeier sold 10,750 shares of the firm’s stock in a transaction that occurred on Tuesday, March 3rd. The stock was sold at an average price of $28.53, for a total value of $306,697.50. Following the completion of the transaction, the chief operating officer now owns 85,750 shares in the company, valued at approximately $2,446,447.50. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CTO Dale Sanders sold 27,500 shares of the firm’s stock in a transaction that occurred on Tuesday, March 3rd. The shares were sold at an average price of $28.46, for a total value of $782,650.00. Following the completion of the transaction, the chief technology officer now owns 88,728 shares of the company’s stock, valued at approximately $2,525,198.88. The disclosure for this sale can be found here. In the last quarter, insiders sold 134,957 shares of company stock valued at $3,623,758. Company insiders own 22.10% of the company’s stock.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Norwest Venture Partners XI LP purchased a new position in shares of Health Catalyst in the 4th quarter valued at approximately $102,438,000. Norwest Venture Partners XII LP bought a new stake in shares of Health Catalyst in the 4th quarter worth $102,438,000. Janus Henderson Group PLC increased its holdings in shares of Health Catalyst by 720.4% in the 1st quarter. Janus Henderson Group PLC now owns 1,178,704 shares of the company’s stock worth $30,823,000 after purchasing an additional 1,035,031 shares in the last quarter. Alliancebernstein L.P. increased its holdings in shares of Health Catalyst by 59.1% in the 1st quarter. Alliancebernstein L.P. now owns 1,160,941 shares of the company’s stock worth $30,359,000 after purchasing an additional 431,183 shares in the last quarter. Finally, Wells Fargo & Company MN grew its holdings in shares of Health Catalyst by 503.2% in the first quarter. Wells Fargo & Company MN now owns 1,111,455 shares of the company’s stock worth $29,064,000 after acquiring an additional 927,194 shares during the period. Institutional investors own 71.23% of the company’s stock.

About Health Catalyst

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations primarily in the United States. The company operates through two segments, Technology and Professional services. Its products include cloud-based data platform, analytics software, and professional services.

Recommended Story: Nikkei 225 Index

Get a free copy of the Zacks research report on Health Catalyst (HCAT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Health Catalyst Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Health Catalyst and related companies with MarketBeat.com's FREE daily email newsletter.